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OBJECTIVES: Assess the clinimetric properties of the
MIGRAINE-SCREEN-Q (MS-Q) questionnaire for the screen-
ing of patients with migraine in the general population.
METHODS: A 16-item tool was developed from the Interna-
tional Headache Criteria (IHS) of Migraine and a review of the
literature by a panel of 6 experts in neurology, occupational med-
icine, clinimetrics, and methodology. The MS-Q instrument was
mailed and ﬁlled in by the employees working for at least 3
months at the Pﬁzer company (Step I) and self-administered to
patients of a Neurological Clinic (Step II and III) in Spain. All
subjects were subsequently referred for an independent diagno-
sis by a neurologist, blinded of MS-Q results. The diagnosis was
assigned according to IHS criteria. Statistical methods included
logistic regression, ROC curves analysis and determination of
sensitivity, speciﬁcity, and positive and negative predictive values
with its 95% conﬁdence interval. RESULTS: In all, 415 employ-
ees (Step I) and 50 patients (Step II) were recruited. Of them,
325 subjects were evaluable and diagnosed as having migraine
(n = 85), other headaches (n = 80) and non-headache subjects (n
= 160). A further 140 patients were recruited in a Neurological
Clinic and analysed independently to get a sample of 70 migraine
and 70 non-migraine patients (Step III). A ﬁve-item subset
(headache frequency and severity, 4 hours’ to 3 days’ duration,
nausea, sensitivity to light/noise and disability) out of 16 pre-
liminary items was derived by logistic regression analyses. A cut-
off of 4 or more points provided a sensitivity of 0.93 (95%CI,
0.87–0.99), speciﬁcity of 0.81 (0.72–0.91), a positive predictive
value of 0.83 (0.75–0.91) and a negative predictive value of 0.92
(0.85–0.99). The reliability Cronbach Alpha coefﬁcient was
0.82. CONCLUSIONS: The 5-item MIGRAINE SCREEN-Q
instrument was found to be a valid and reliable screening tool
for migraine headaches. Further studies are warranted to test its
applicability in the general population.
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OBJECTIVE: IRLS is used for clinical assessment and severity
of Restless Legs Syndrome (RLS). To compare the burden of RLS
with other health states, this study has mapped the IRLS to a
multi-attribute utility measure, the EQ-5D. METHODS: Four
RLS experts from Spain, France, UK and US were identiﬁed to
participate in mapping the ten IRLS items (each with ﬁve ordinal
response levels) to the ﬁve EQ-5D domains (each with three
ordinal response levels). A pilot study conducted by one expert
identiﬁed two issues: 1) the disease characteristics of RLS and
the 10 IRLS items could not be mapped to EQ-5D domains of
“Self-care” and “Mobility” (EQ-5D level “1” was assigned to
both), and 2) IRLS question three (relating to relief from move-
ment) proved difﬁcult to map; an algorithm to map this was
developed. All experts then completed their individual mapping
responses. Discrepancies were resolved through consensus result-
ing in one ﬁnal mapping response. RESULTS: The experts con-
cluded that the EQ-5D domains of “Pain/Discomfort”, “Usual
Activities” and “Anxiety/Depression” were appropriate for
mapping to the 10 IRLS items (each item mapped once).
“Pain/Discomfort” mapped to four IRLS items, “Usual Activi-
ties” mapped to ﬁve IRLS items and “Anxiety/Depression”
mapped to one IRLS item. Ordinal responses for each IRLS item
were mapped to appropriate ordinal responses on the three EQ-
5D domains. EQ-5D utilities could be established for different
combinations of IRLS item responses and corresponding IRLS
total scores. Using trial data, a signiﬁcant correlation between
IRLS total scores and EQ-5D utilities was established (r = -0.84,
p < 0.0001). CONCLUSION: Based on clinical consensus, the
IRLS can be successfully mapped to the EQ-5D. The algorithm
resulting from this work may be used to compare health related
QoL of RLS sufferers with those of other diseases for resource
allocation decisions.
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OBJECTIVES: The development of Markov decision models for
chronic diseases is often time-consuming and sophisticated.
Therefore, generic and ﬂexible models have advantages. We
present a method that allows to externally adjust decision models
for context-speciﬁc variables such as epidemiologic, clinical, or
economic parameters. METHODS: To allow transfer of decision
models across populations or countries with correct adjustment
for context-speciﬁc parameters, we used centered regression
equations instead of ﬁxed values as model parameters. Clinical
event probabilities, utilities, and costs were deﬁned as functions
of context-speciﬁc predictors. Centering the predictors on their
means allows to interpret intercepts as grand means and regres-
sion coefﬁcients as relative modiﬁers. We applied this approach
to the Parkinson’s Disease Model (PDM) using 1-year follow-up
data of target outcomes (clinical events, utilities [EQ-5D], and
costs) from the German Parkinson’s Disease Competence
Network Study (n = 145). We validated the centered regression
approach by comparing model results to those from models with
model parameters based on non-centered regression and ﬁxed
parameters values. RESULTS: Target outcomes of PDM were
deﬁned by 1) centered regression equations; 2) intercepts repre-
senting grand means of 1-year target outcomes (anchor value);
3) distribution of disease severity stages; and 4) regression coef-
ﬁcients for each stage representing additive (utilities) or multi-
plicative (events, costs) modiﬁers for the anchor value. Assuming
constant modiﬁers, the model can be transferred if data on mean
outcomes and severity stage distribution of the target country are
available. Sensitivity analyses were facilitated, as changes in
overall event risk, utilities, or costs were achieved by simply
changing intercepts. Validation of the centered regression-based
PDM with non-centered regression equations or using ﬁxed
values in the model led to identical results. CONCLUSIONS:
The implementation of centered regression-based equations in a
decision model enhances model ﬂexibility with respect to sensi-
tivity analyses and transferability to another population or
health care context.
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OBJECTIVES: Estimating the cost of a disease for Europe is a
methodological challenge due to differences in epidemiology,
